Formulation of Lipid Nanoparticles based Nanogel of Sertaconazole Nitrate and its Evaluation

Q3 Medicine
Sarvesh S. Pawar, Punam S. Gadekar, Bhushan R. Rane, Ashish S. Jain
{"title":"Formulation of Lipid Nanoparticles based Nanogel of Sertaconazole Nitrate and its Evaluation","authors":"Sarvesh S. Pawar, Punam S. Gadekar, Bhushan R. Rane, Ashish S. Jain","doi":"10.2174/0124681873255919231002044416","DOIUrl":null,"url":null,"abstract":"Background: Sertaconazole nitrate is a topical antifungal drug used to treat interdigital tinea pedis in patients with immunocompetent conditions. The class of imidazole includes the antifungal medication sertaconazole nitrate. It is available in topical formulations for treating skin infections, including athlete's foot. Solid lipid nanoparticles (SLN) are at the cutting edge of nanotechnology, with several potential uses in drug delivery and research. Because of their unique size-dependent features, lipid nanoparticles hold the promise of novel therapies. Objective: Drug incorporation into nanocarriers creates a new drug delivery prototype that could be employed for drug targeting. The research aims to study the formulation and evaluation of Sertaconazole nitrate solid lipid nanoparticles. The goal behind formulating SLN gel is to provide and maintain therapeutic concentrations of the drug at the target biological site to maximise therapeutic efficacy and minimise side effects. Methods: Sertaconazole Nitrate Solid Lipid Nanoparticles are prepared by using High Pressure Homogenizer to get nanogel formulation as the final formulation and In-vitro drug release using a diffusion apparatus. The prepared SLNs were evaluated in their FTIR studies to determine compatibility between the drug and the excipients; zeta potential indicates the solid lipid nanoparticle was stable, and polydispersity index was used to determine particle size. Result: The results demonstrate that optimised SLN-based Sertaconazole nitrate gel exhibited the best physicochemical properties, including FTIR studies of the drug, excipients, and optimised formulation demonstrate that all are compatible with each other, particle size is less than 200 nm, zeta potential ranging from 12 to -20 mV, and highest entrapment efficiency is 71.48%. Optimised solid lipid nanoparticles showed good in vitro release and antimicrobial results. The main application of SLN large scale-up is possible, and the drug can be effective with less dose incorporation. Conclusion: In this research work, the proposed plan of work SLN of Sertaconazole Nitrate was formulated successfully. The preliminary identification tests were performed, such as melting point determination, estimation of λmax by UV-visible spectrophotometry and plot of its calibration curve in solvent and buffer system, and FT-IR investigation to confirm the purity and confirmation of medication. High physical stability and drug loading are advantageous to SLN.","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":"89 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Nanomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0124681873255919231002044416","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Sertaconazole nitrate is a topical antifungal drug used to treat interdigital tinea pedis in patients with immunocompetent conditions. The class of imidazole includes the antifungal medication sertaconazole nitrate. It is available in topical formulations for treating skin infections, including athlete's foot. Solid lipid nanoparticles (SLN) are at the cutting edge of nanotechnology, with several potential uses in drug delivery and research. Because of their unique size-dependent features, lipid nanoparticles hold the promise of novel therapies. Objective: Drug incorporation into nanocarriers creates a new drug delivery prototype that could be employed for drug targeting. The research aims to study the formulation and evaluation of Sertaconazole nitrate solid lipid nanoparticles. The goal behind formulating SLN gel is to provide and maintain therapeutic concentrations of the drug at the target biological site to maximise therapeutic efficacy and minimise side effects. Methods: Sertaconazole Nitrate Solid Lipid Nanoparticles are prepared by using High Pressure Homogenizer to get nanogel formulation as the final formulation and In-vitro drug release using a diffusion apparatus. The prepared SLNs were evaluated in their FTIR studies to determine compatibility between the drug and the excipients; zeta potential indicates the solid lipid nanoparticle was stable, and polydispersity index was used to determine particle size. Result: The results demonstrate that optimised SLN-based Sertaconazole nitrate gel exhibited the best physicochemical properties, including FTIR studies of the drug, excipients, and optimised formulation demonstrate that all are compatible with each other, particle size is less than 200 nm, zeta potential ranging from 12 to -20 mV, and highest entrapment efficiency is 71.48%. Optimised solid lipid nanoparticles showed good in vitro release and antimicrobial results. The main application of SLN large scale-up is possible, and the drug can be effective with less dose incorporation. Conclusion: In this research work, the proposed plan of work SLN of Sertaconazole Nitrate was formulated successfully. The preliminary identification tests were performed, such as melting point determination, estimation of λmax by UV-visible spectrophotometry and plot of its calibration curve in solvent and buffer system, and FT-IR investigation to confirm the purity and confirmation of medication. High physical stability and drug loading are advantageous to SLN.
硝酸舍他康唑脂质纳米凝胶的制备及评价
背景:硝酸舍他康唑是一种局部抗真菌药物,用于治疗免疫功能正常患者的指间足癣。咪唑类药物包括抗真菌药物硝酸舍他康唑。它可用于局部配方治疗皮肤感染,包括脚气。固体脂质纳米颗粒(SLN)处于纳米技术的前沿,在药物输送和研究中具有几种潜在的用途。由于其独特的尺寸依赖性,脂质纳米颗粒有望成为新的治疗方法。目的:将药物掺入纳米载体中,为药物靶向治疗提供一种新的给药原型。本研究旨在研究硝酸舍他康唑固体脂质纳米颗粒的制备及性能评价。制定SLN凝胶的目的是在目标生物部位提供和维持药物的治疗浓度,以最大限度地提高治疗效果并减少副作用。方法:采用高压均质机制备硝酸舍他康唑固体脂质纳米颗粒,得到纳米凝胶制剂作为最终制剂,并采用扩散装置体外释放。制备的sln在FTIR研究中进行评估,以确定药物与辅料之间的相容性;Zeta电位表明固体脂质纳米颗粒是稳定的,并用多分散性指数来确定颗粒大小。结果:优化后的sln基硝酸塞尔达康唑凝胶具有最佳的理化性能,对药物、辅料及优化配方的FTIR研究表明,三者相容性良好,粒径小于200 nm, zeta电位范围在12 ~ -20 mV之间,最高包封效率为71.48%。优化后的固体脂质纳米颗粒具有良好的体外释放效果和抗菌效果。SLN的主要应用是大规模的,并且药物可以在较少的剂量掺入下有效。结论:在本研究工作中,成功制定了硝酸舍他康唑工作SLN的拟定方案。进行了熔点测定、紫外可见分光光度法测定λmax并绘制其在溶剂和缓冲体系中的校准曲线、FT-IR研究以确定其纯度和药物的确认。具有较高的物理稳定性和载药量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Nanomedicine
Current Nanomedicine Medicine-Medicine (miscellaneous)
CiteScore
2.00
自引率
0.00%
发文量
15
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信